The FDA approved the CDK4/6 inhibitors ribociclib and palbociclib in combination with an aromatase inhibitor for first-line therapy in hormone receptor–positive, HER2-negative breast cancer (19, 21, 22). Here, ERBB2 is linked to breast carcinoma.